title: A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population.
abstract: MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF), play a pivotal role in the activties of tumor cells. A germline missense variant in exon 2 of the MET gene, N375S (rs33917957 A>G), may alter the binding affinity of MET for HGF and thus modify the risk of tumorigenesis. In this study, we performed a case-control study to assess the association between N375S and gastric cancer risk in 1,681 gastric cancer cases and 1,858 cancer-free controls. Logistic regression analysis was applied to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between genotypes and gastric cancer risk. We found that MET N375S variant genotypes (NS/SS) were associated with a significantly decreased risk of gastric cancer (OR = 0.78, 95% CI = 0.63-0.96, P = 0.021) compared with the wildtype homozygote (NN). The finding indicates that this germline variant in MET may decrease gastric cancer susceptibility in Han Chinese.
authors.affiliation: Department of Epidemiology and Biostatistics, MOE Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210029, China;
authors.forename: Yao
authors.initials: Y
authors.lastname: Liu
authors.forename: Qin
authors.initials: Q
authors.lastname: Zhang
authors.forename: Chuanli
authors.initials: C
authors.lastname: Ren
authors.forename: Yanbing
authors.initials: Y
authors.lastname: Ding
authors.forename: Guangfu
authors.initials: G
authors.lastname: Jin
authors.forename: Zhibin
authors.initials: Z
authors.lastname: Hu
authors.forename: Yaochu
authors.initials: Y
authors.lastname: Xu
authors.forename: Hongbing
authors.initials: H
authors.lastname: Shen
keywords: MET; gastric cancer; germline variation; susceptibility
references.citation: Oncogene. 2000 Oct 12;19(43):4947-53
references.pmid: 11042681
references.citation: Gastroenterology. 1997 May;112(5):1457-65
references.pmid: 9136822
references.citation: Clin Cancer Res. 2009 Sep 15;15(18):5714-23
references.pmid: 19723643
references.citation: Int J Cancer. 1993 Aug 19;55(1):72-5
references.pmid: 8344755
references.citation: N Engl J Med. 2000 Jul 13;343(2):78-85
references.pmid: 10891514
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):75-8
references.pmid: 11205493
references.citation: Int J Cancer. 2010 Nov 1;127(9):2183-9
references.pmid: 20131315
references.citation: Carcinogenesis. 2011 Jun;32(6):848-52
references.pmid: 21427165
references.citation: Trends Cell Biol. 1998 Oct;8(10):404-10
references.pmid: 9789329
references.citation: IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241
references.pmid: 7715068
references.citation: Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
references.pmid: 14685170
references.citation: Cancer. 1999 May 1;85(9):1894-902
references.pmid: 10223227
references.citation: Oncology. 2002;63(3):286-96
references.pmid: 12381909
references.citation: Int J Cancer. 2000 Nov 15;88(4):601-6
references.pmid: 11058877